Diabetes Clinical Research Corner Update

Mount Sinai is dedicated to diabetes research.  Below are research studies that are currently underway, recruiting, or completed.  If you are interested in becoming a research volunteer reach out to Camilla Levister, NP at 212-241-5177 or our research coordinator at 212 241-9089:

• PERL (Prevention of Early Renal Loss in Diabetes): This is an exciting and landmark National Institutes of Health-sponsored study to explore if a pill that has commonly been used for other conditions can prevent the progression of kidney damage caused by type 1 diabetes.  .   Recruitment ends October 31^st.You can learn more by going to www.perl-study.org

• Artificial Pancreas Program:  If you are interested in participating in future Artificial Pancreas Studies, contact Camilla Levister, NP at 212-241-5177.

• TrialNet, Pathway to Prevention:  This is a study jointly funded by ADA, JDRF, NIDDK and others, being conducted at 18 Clinical Centers in 8 countries and studies those at increased risk for type 1 diabetes.  If you are 1-45 years old and the 1^st degree relative of a person with type 1 diabetes, you may be eligible to participate.  Second degree relatives (cousins, uncles, nieces, nephews, half siblings, or grandparents) of someone with type 1 diabetes between the ages of 1 and 20 years old may also be eligible.  This study is currently recruiting.  Contact our research coordinator for further information at 212 241-9089.

• Victoza (liraglutide) use in type 1 diabetes:  This study explored the efficacy of liraglutide in patients with type 1 diabetes in improving glycemic control, reducing total daily insulin requirements, and body weight loss.  This study is currently completed and we look forward to hearing about the results when the data from all sites is fully analyzed. 

• Faster acting insulin aspart (FIAsp):  This study is currently completed.  FIAsp is a new and faster formation of insulin aspart, a type of rapid acting insulin.  This trial explored the efficacy of FIAsp in diabetes management as measured by hemoglobin A1c and finger stick glucose values after meals.  We look forward to the results of data analysis for this multisite study. 

• Sotogaflozin use in type 1 diabetes: This is a study assessing the benefits of an SGLT 1/SGLT 2 inhibitor as adjunctive therapy in the management of type 1 diabetes; this study will likely be opening mid September 2015. 

Additional studies will soon be starting for type 1 and type 2 diabetes.  Please call 212 241-5177 or 212 241-9089 if you would like to additional information regarding current or  upcoming studies.